Study on salivary tumor markers in diagnosis of pancreatic cancer

doi:10.16139/j.1007-9610.2019.02.013

Abstract

Abstract: Objective To analyze salivary tumor markers in diagnosis and evaluation of pancreatic cancer. Methods Twenty-six patients with pancreatic cancer, 9 patients with benign pancreatic tumor and 16 healthy controls were involved. We compared the concentrations of salivary tumor markers including AFP, CEA, CA125, CA19-9, CA724 and CA242 in three groups to find the tumor marker to diagnose pancreatic cancer and the biomarker associated with the patients of local advanced pancreatic cancer. The tumor marker associated with survival of pancreatic cancer was also studied. Results Salivary AFP, CEA, CA125 and CA724 in the patients with pancreatic cancer were higher when compared those in patients with benign pancreatic tumor and in healthy controls. The difference of salivary tumor markers was present significantly between pancreatic cancer group and control group (P< 0.05). Salivary CEA and CA125 to diagnose pancreatic cancer had area under curve 0.91 and 0.94, respectively. Both tumor markers got same sensitivity 92.31% and same specificity 84.62%. Salivary CEA and CA125 were associated with the patients of survival less half year and with the patients of locally advanced pancreatic cancer significantly (P< 0.05). Conclusions The results showed that salivary tumor markers CEA and CA125 could be used in diagnosis of pancreatic cancer at some extent and further study is needed.

Key words: Pancreatic cancer, Tumor marker, Saliva, Diagnosis

CLC Number:

R735.9

ZHAO Zhifeng, XIE Rongli, SHEN Dongjie, ZHANG Jun, XU Zhiwei, CHENG Dongfeng, FEI Jian, DENG Xiaxing, SHEN Baiyong, PENG Chenghong. Study on salivary tumor markers in diagnosis of pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2019, 24(02): 149-154.

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] Sommerville CA, Limongelli P, Pai M, et al.Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors[J]. J Surg Oncol,2009,100(8):651-656.
[3] Winter JM, Cameron JL, Campbell KA, et al.1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience[J]. J Gastrointest Surg,2006,10(9):1199-1211.
[4] Forsmark CE, Lambiase L, Vogel SB.Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9[J]. Pancreas,1994,9(6):731-734.
[5] Porto-Mascarenhas EC, Assad DX, Chardin H, et al.Salivary biomarkers in the diagnosis of breast cancer: a review[J]. Crit Rev Oncol Hematol,2017,110:62-73.
[6] Xiao H, Zhang L, Zhou H, et al.Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry[J]. Mol Cell Proteomics,2012,11(2):M111.
[7] 白雪莉, 马涛, 梁廷波. 美国癌症联合委员会第8版胰腺癌分期系统更新简介及解读[J]. 中国实用外科杂志,2017,37(2):55-57.
[8] Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A.Correlation of serum and salivary CA15-3 levels in patients with breast cancer[J]. Med Oral,2009,14(10):e521-e524.
[9] Dyckhoff G, Warta R, Gonnermann A, et al.Carbohydrate antigen 19-9 in saliva: possible preoperative marker of malignancy in parotid tumors[J]. Otolaryngol Head Neck Surg,2011,145(5):772-777.
[10] Kim YC, Kim HJ, Park JH, et al.Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?[J]. J Gastroenterol Hepatol,2009,24(12):1869-1875.
[11] Duffy MJ, Sturgeon C, Lamerz R, et al.Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report[J]. Ann Oncol,2010,21(3):441-447.
[12] Chen T, Zhang MG, Xu HX, et al.Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma[J]. Medicine (Baltimore),2015,94(19):e751.
[13] Tibbetts LM, Doremus CM, Tzanakakis GN, et al.Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production[J]. Cancer,1993,71(2):315-321.
[14] Poruk KE, Gay DZ, Brown K, et al.The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates[J]. Curr Mol Med,2013,13(3):340-351.
[15] Fujioka S, Misawa T, Okamoto T, et al.Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma[J]. J Hepatobiliary Pancreat Surg,2007,14(6):539-544.
[16] Haridas D, Chakraborty S, Ponnusamy MP, et al.Pathobiological implications of MUC16 expression in pancrea-tic cancer[J]. PLoS ONE,2011,6(10):e26839.
[17] Cwik G, Wallner G, Skoczylas T, et al.Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions[J]. Arch Surg,2006,141(10):968-974.
[18] Hofman LF.Human saliva as a diagnostic specimen[J]. J Nutr,2001,131(5):1621S-1625S.
[19] Liu J, Duan Y.Saliva: a potential media for disease dia-gnostics and monitoring[J]. Oral Oncol,2012,48(7):569-577.
[20] Loo JA, Yan W, Ramachandran P, et al.Comparative human salivary and plasma proteomes[J]. J Dent Res,2010, 89(10):1016-1023.
[21] Pfaffe T, Cooper-White J, Beyerlein P, et al.Diagnostic potential of saliva: current state and future applications[J]. Clin Chem,2011,57(5):675-687.
[22] Lee KJ, Yi SW, Chung MJ, et al.Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma[J]. Yonsei Med J,2013,54(3):643-649.
[23] Park NJ, Li Y, Yu T, et al.Characterization of RNA in saliva[J]. Clin Chem,2006,52(6):988-994.
[24] Park NJ, Yu T, Nabili V, et al.RNAprotect saliva: An optimal room- temperature stabilization reagent for the salivary transcriptome[J]. Clin Chem,2006,52(12):2303-2304.
[25] Zhang L, Farrell JJ, Zhou H, et al.Salivary transcripto-mic biomarkers for detection of resectable pancreatic cancer[J]. Gastroenterology,2010,138(3):949-957.
[26] Xie Z, Chen X, Li J, et al.Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer[J]. Oncotarget,2016,7(18):25408-25419.
[27] Benishay O, Haim SO, Kaplan M, et al.CA19-9 levels in saliva and urine of patients with ductal adenocarcinoma of the pancreas correlates with serum CA19-9 levels-a prospective preliminary study[J]. J Pancreas,2016,17(1):66-69.
[28] Kefalides PT.Saliva research leads to new diagnostic tools and therapeutic options[J]. Ann Intern Med,1999, 131(12):991-992.